SEB Concept Biotechnology Fund D
Equity fund
1 year
USA
Largest region
High
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- Fondet plasserer over hele verden i aksjer og aksjerelaterte verdipapir i bioteknologisektoren. Investeringene gjøres i selskaper som fokuserer på forskning, utvikling samt produksjon og distribusjon av bioteknologi og medisiner.
Investment horizon
- SEB Concept Biotechnology Fund D is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
03 Sept 2025
- Start date15 Oct 2000
- ISINLU0118405827
Risk
- High (5 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Annual cost
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
Other costs
- Performance-based fee
- Transaction costs
Costs for any currency exchanges are not included.
Allocation
- Stocks 99%Interest 1%
Portfolio
Shows the fund's largest investments.
- Gilead Sciences Inc8.9%
- Amgen Inc8.7%
- Vertex Pharmaceuticals Inc8.0%
- Alnylam Pharmaceuticals Inc6.7%
- Verona Pharma PLC ADR4.9%
- Regeneron Pharmaceuticals Inc4.8%
- AstraZeneca PLC ADR4.6%
- argenx SE ADR2.9%
- BioNTech SE ADR2.4%
- Insmed Inc2.3%